Larimar Therapeutics (LRMR) Stock Forecast, Price Target & Predictions

LRMR Stock Forecast

Larimar Therapeutics stock forecast is as follows: an average price target of $20.33 (represents a 234.37% upside from LRMR’s last price of $6.08) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

LRMR Price Target

The average price target for Larimar Therapeutics (LRMR) is $20.33 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $25.00 to $14.00. This represents a potential 234.37% upside from LRMR's last price of $6.08.

LRMR Analyst Ratings

Buy

According to 5 Wall Street analysts, Larimar Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for LRMR stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Larimar Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 30, 2024	Samantha Semenkow	Citigroup	$14.00	$8.46	65.48%	130.26%
Oct 03, 2024	Laura Chico	Wedbush	$22.00	$6.29	249.76%	261.84%
Apr 03, 2024	Joori Park	Leerink Partners	$25.00	$7.57	230.25%	311.18%
Dec 13, 2022	-	Citigroup	$4.00	$3.97	0.76%	-34.21%

Row per page

Go to

The latest Larimar Therapeutics stock forecast, released on Oct 30, 2024 by Samantha Semenkow from Citigroup, set a price target of $14.00, which represents a 65.48% increase from the stock price at the time of the forecast ($8.46), and a 130.26% increase from LRMR last price ($6.08).

Larimar Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	1	2	3
Avg Price Target	$14.00	$18.00	$20.33
Last Closing Price	$6.08	$6.08	$6.08
Upside/Downside	130.26%	196.05%	234.37%

In the current month, the average price target of Larimar Therapeutics stock is $14.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 130.26% increase as opposed to Larimar Therapeutics's last price of $6.08. This month's average price target is down -22.22% compared to last quarter, and down -31.14% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 30, 2024	Citigroup	Buy	Buy	Hold
Oct 15, 2024	Oppenheimer	-	Outperform	Initialise
Oct 03, 2024	Wedbush	-	Outperform	Initialise
Oct 02, 2024	H.C. Wainwright	-	Buy	Initialise
May 22, 2024	Citigroup	Buy	Buy	Hold
May 21, 2024	William Blair	Outperform	Outperform	Hold
May 21, 2024	William Blair	Hold	Hold	Hold
Dec 13, 2022	Citigroup	-	Neutral	Initialise
Sep 19, 2022	William Blair	-	Outperform	Upgrade

Row per page

Go to

Larimar Therapeutics's last stock rating was published by Citigroup on Oct 30, 2024. The company gave LRMR a "Buy" rating, the same as its previous rate.

Larimar Therapeutics Financial Forecast

Larimar Therapeutics Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
Revenue	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-	-	-	-	-
# Analysts	-	-	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-

Larimar Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. LRMR's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Larimar Therapeutics EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-

undefined analysts predict LRMR's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Larimar Therapeutics's previous annual EBITDA (undefined) of $NaN.

Larimar Therapeutics Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-	-	-	-	-
Net Income	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$-27.98M	$-27.71M	$-27.29M	$-27.38M	$-27.50M	$-25.70M	$-22.97M	$-20.66M	$-19.68M	$-23.91M	$-19.48M
High Forecast	$-27.98M	$-27.71M	$-27.29M	$-27.38M	$-27.50M	$-25.70M	$-22.97M	$-16.66M	$-16.96M	$-23.91M	$-19.48M
Low Forecast	$-27.98M	$-27.71M	$-27.29M	$-27.38M	$-27.50M	$-25.70M	$-22.97M	$-23.99M	$-21.04M	$-23.91M	$-19.48M
Surprise %	-	-	-	-	-	-	-	-	-	-	-

Larimar Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. LRMR's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Larimar Therapeutics SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-	-	-	-	-
SG&A	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-

Larimar Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to LRMR last annual SG&A of $NaN (undefined).

Larimar Therapeutics EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-	-	-	-	-
EPS	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$-0.44	$-0.43	$-0.43	$-0.43	$-0.43	$-0.40	$-0.36	$-0.32	$-0.31	$-0.37	$-0.31
High Forecast	$-0.44	$-0.43	$-0.43	$-0.43	$-0.43	$-0.40	$-0.36	$-0.26	$-0.27	$-0.37	$-0.31
Low Forecast	$-0.44	$-0.43	$-0.43	$-0.43	$-0.43	$-0.40	$-0.36	$-0.38	$-0.33	$-0.37	$-0.31
Surprise %	-	-	-	-	-	-	-	-	-	-	-

According to undefined Wall Street analysts, Larimar Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to LRMR previous annual EPS of $NaN (undefined).

Larimar Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
IMRX	Immuneering	$2.04	$17.50	757.84%	Buy
SPRO	Spero Therapeutics	$1.20	$10.00	733.33%	Buy
CHRS	Coherus BioSciences	$1.10	$9.00	718.18%	Hold
CABA	Cabaletta Bio	$2.26	$16.33	622.57%	Buy
STRO	Sutro Biopharma	$2.67	$11.14	317.23%	Buy
LRMR	Larimar Therapeutics	$6.08	$20.33	234.38%	Buy
FIXX	Q32 Bio	$0.93	$2.70	190.32%	Buy
DAWN	Day One Biopharmaceuticals	$13.62	$38.80	184.88%	Buy
CELC	Celcuity	$12.78	$31.50	146.48%	Buy
KZR	Kezar Life Sciences	$7.49	$17.50	133.64%	Buy
SNDX	Syndax Pharmaceuticals	$15.95	$34.30	115.05%	Buy
KROS	Keros Therapeutics	$54.14	$102.60	89.51%	Buy
MRUS	Merus	$42.93	$77.13	79.66%	Buy
BOLT	Bolt Biotherapeutics	$0.57	$1.00	75.44%	Hold
PCVX	Vaxcyte	$85.96	$124.00	44.25%	Buy
CNTA	Centessa Pharmaceuticals	$16.74	$23.25	38.89%	Buy
ALEC	Alector	$3.64	$4.00	9.89%	Buy
IKNA	Ikena Oncology	$1.70	$1.33	-21.76%	Buy
GRCL	Gracell Bio	$10.25	$6.00	-41.46%	Buy

LRMR Forecast FAQ

Is Larimar Therapeutics a good buy?

Yes, according to 5 Wall Street analysts, Larimar Therapeutics (LRMR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of LRMR's total ratings.

What is LRMR's price target?

Larimar Therapeutics (LRMR) average price target is $20.33 with a range of $14 to $25, implying a 234.37% from its last price of $6.08. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Larimar Therapeutics stock go up soon?

According to Wall Street analysts' prediction for LRMR stock, the company can go up by 234.37% (from the last price of $6.08 to the average price target of $20.33), up by 311.18% based on the highest stock price target, and up by 130.26% based on the lowest stock price target.

Can Larimar Therapeutics stock reach $9?

LRMR's average twelve months analyst stock price target of $20.33 supports the claim that Larimar Therapeutics can reach $9 in the near future.

What is Larimar Therapeutics's current price target trend?

1 Wall Street analyst forecast a $14 price target for Larimar Therapeutics (LRMR) this month, up 130.26% from its last price of $6.08. Compared to the last 3 and 12 months, the average price target increased by 196.05% and increased by 234.37%, respectively.

What are Larimar Therapeutics's analysts' financial forecasts?

Larimar Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-96.832M (high $-92.833M, low $-100M), average SG&A $0 (high $0, low $0), and average EPS is $-1.518 (high $-1.455, low $-1.57). LRMR's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-110M (high $-110M, low $-110M), average SG&A $0 (high $0, low $0), and average EPS is $-1.73 (high $-1.73, low $-1.73).